Évaluation de l'impact clinique et économique du développement d'un traitement pour la schizophrénie

摘要: Aim: Pharmacological strategies for schizophrenia have received increasing attention due to the development of new therapies more effective, better tolerated but expensive. Schizophrenia is a chronic illness with various states illness. Objectives: This research program aimed: 1) evaluate factors associated risk being in specific state order construct functions course modeling; 2) develop and validate Markov model MonteCarlo micro-simulations simulate natural patients who been newly diagnosed schizophrenic based upon individual profile; 3) estimate direct healthcare non-healthcare cost clinical economic impact developing treatment, cohort schizophrenia, over first 5 years following their diagnosis. Methods: For objective this program, total 14,320 were identified on data from RAMQ Med-Echo databases. Six disorder defined: episode (FE), low dependency (LDS), high (HDS), Stable (Stable), Well (Well) Death (Death). To each disease state, we constructed 4 Cox proportional hazard analysis competing risks. second objective, Monte-Carlo microsimulations six was developed validated. In model, subject had his own probabilities transition between states, which estimated cumulative incidence function. third objected, used previously developed. The includes costs Regie de l’assurance maladie du Quebec databases surveys publications Statistics Canada.